X

Trial Profile

A Phase Ib study of eltrombopag and azacitidine in patients with high risk myelodysplastic syndromes and related disorders

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Eltrombopag (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Acronyms ELASTIC

Most Recent Events

01 Oct 2022 Results assessing the safety of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders published in the British Journal of Haematology
08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
10 Jul 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com